Galectin Therapeutics Reported The Outcome Of Its Third Data And Safety Monitoring Board Meeting For NAVIGATE Phase 2B/3 Study Of Belapectin For Liver Cirrhosis Caused By NASH, Interim Data From The Phase 2B Portion Is Expected In Q4 Of 2024

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!